Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
- PMID: 15960775
- DOI: 10.1111/j.1466-5468.2005.01711c.x
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
Similar articles
-
Insulin sensitizer affects lipids.Health News. 2005 Jan;11(1):2. Health News. 2005. PMID: 15726701 No abstract available.
-
Thiazolidinediones in type 2 diabetes: a cardiology perspective.Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18698014 Review.
-
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Diabetes Metab Res Rev. 2009. PMID: 19219860 Review.
-
[Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].Ugeskr Laeger. 2007 Nov 19;169(47):4054-7. Ugeskr Laeger. 2007. PMID: 18078659 Review. Danish. No abstract available.
-
Type 2 diabetes, psoriasis and thiazolidinediones.Int J Clin Pract. 2006 Mar;60(3):362-3. doi: 10.1111/j.1368-5031.2005.00765.x. Int J Clin Pract. 2006. PMID: 16494655
Cited by
-
Rosiglitazone for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD006063. doi: 10.1002/14651858.CD006063.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636824 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical